KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

11.18 (USD) • At close November 7, 2024
Bedrijfsnaam KalVista Pharmaceuticals, Inc.
Symbool KALV
Munteenheid USD
Prijs 11.18
Beurswaarde 483,149,290
Dividendpercentage 0%
52-weken bereik 7.21 - 16.88
Industrie Biotechnology
Sector Healthcare
CEO Mr. Thomas Andrew Crockett M.B.A.
Website https://www.kalvista.com

An error occurred while fetching data.

Over KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a

Vergelijkbare Aandelen

Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc.

COGT

10.05 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

3.12 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

1.27 USD

bluebird bio, Inc. logo

bluebird bio, Inc.

BLUE

0.382 USD

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

9 USD

MacroGenics, Inc. logo

MacroGenics, Inc.

MGNX

4.46 USD

Singular Genomics Systems, Inc. logo

Singular Genomics Systems, Inc.

OMIC

23.3 USD

PepGen Inc. logo

PepGen Inc.

PEPG

5.63 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)